Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Equillium (EQ) Research & Development (2022 - 2025)

Equillium (EQ) has disclosed Research & Development for 4 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 86.39% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.6 million, a 52.61% decrease, with the full-year FY2024 number at $37.4 million, up 1.05% from a year prior.
  • Research & Development was $1.3 million for Q3 2025 at Equillium, down from $4.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $10.8 million in Q2 2024 to a low of $1.3 million in Q3 2025.
  • A 4-year average of $8.2 million and a median of $9.2 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: increased 12.47% in 2024, then crashed 86.39% in 2025.
  • Equillium's Research & Development stood at $8.5 million in 2022, then grew by 7.73% to $9.2 million in 2023, then decreased by 20.35% to $7.3 million in 2024, then crashed by 82.21% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for EQ's Research & Development are $1.3 million (Q3 2025), $4.1 million (Q2 2025), and $5.9 million (Q1 2025).